B‐cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T‐cell precursor acute lymphoblastic leukaemia/lymphoma (ETP‐ALL/LBL) from other subtypes of T‐cell ALL/LBL
Summary B‐cell lymphoma/leukaemia 11B (BCL11B) is an essential transcription factor for T‐cell lineage commitment and maturation. We investigated BCL11B expression by immunohistochemistry in T‐lymphoblastic leukaemia/lymphoma (T‐ALL/LBL) (n = 115). The majority (83%) of early T‐cell precursor T‐ALL/...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2021-09, Vol.194 (6), p.1034-1038 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1038 |
|---|---|
| container_issue | 6 |
| container_start_page | 1034 |
| container_title | British journal of haematology |
| container_volume | 194 |
| creator | Fang, Hong Wang, Wei El Hussein, Siba Morita, Kiyomi Beird, Hannah C. Mitra, Akash Loghavi, Sanam Lin, Pei Jabbour, Elias J. Khoury, Joseph D. |
| description | Summary
B‐cell lymphoma/leukaemia 11B (BCL11B) is an essential transcription factor for T‐cell lineage commitment and maturation. We investigated BCL11B expression by immunohistochemistry in T‐lymphoblastic leukaemia/lymphoma (T‐ALL/LBL) (n = 115). The majority (83%) of early T‐cell precursor T‐ALL/LBL (ETP‐ALL) cases showed negative BCL11B expression, while most (84%) of non‐ETP‐ALL/LBL were positive for BCL11B. A simplified three‐marker [BCL11B, cluster of differentiation 5 (CD5), CD13] immunophenotypic score discriminated reliably between ETP‐ALL and non‐ETP‐ALL/LBL. In ETP‐ALL, patients with positive BCL11B expression had a better overall survival than those with negative BCL11B (P = 0·009). In summary, BCL11B is a valuable marker for T‐ALL/LBL subtyping and serves as a potential prognostic marker in patients with ETP‐ALL. |
| doi_str_mv | 10.1111/bjh.17681 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2562234444</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2562234444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-633a5a39f5aa468315a902932cceb7f6681fa0983213f58fda49cbb879dd24113</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS0EotPCghdAltjMLNL42s7fshkVCopUFsM6chyHZEjGwY5VsuMReKg-CU9ST2emSEi9m7v5zjlX9yD0Dsgl-AmrbXsJSZzCC7QAFkcBBQ4v0YIQkgRAeHqGzq3dEgKMRPAanTHOCSVRukD3-d_ff6Tqe9zPw9jqQYS9cj-EGjqBAXK8zNeF3yusfo1GWdvpHbaTmJzFrepHi-vOTt3uu-tsi5Uw_Yw3J0svkM5YbbCQblLHiKoXXiHxU054isbL681XL74qirDIixVujB6wnlplsHXVNI_KYt38CziCb9CrRvRWvT3uC_Tt4_VmfRMUt58-r6-KQLI0hSBmTESCZU0kBI9TBpHICM0YlVJVSRP7BzaCZCmjwJoobWrBM1lVaZLVNeUA7AItD76j0T-dslM5dHZ_iNgp7WxJo5hS_1vOPfrhP3Srndn56zyV0CxKIN4brg6UNNpao5pyNN0gzFwCKffVlr7a8rFaz74_OrpqUPUTeerSA-EBuOt6NT_vVOZfbg6WDwapsN0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2572957161</pqid></control><display><type>article</type><title>B‐cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T‐cell precursor acute lymphoblastic leukaemia/lymphoma (ETP‐ALL/LBL) from other subtypes of T‐cell ALL/LBL</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Wiley Free Content</source><creator>Fang, Hong ; Wang, Wei ; El Hussein, Siba ; Morita, Kiyomi ; Beird, Hannah C. ; Mitra, Akash ; Loghavi, Sanam ; Lin, Pei ; Jabbour, Elias J. ; Khoury, Joseph D.</creator><creatorcontrib>Fang, Hong ; Wang, Wei ; El Hussein, Siba ; Morita, Kiyomi ; Beird, Hannah C. ; Mitra, Akash ; Loghavi, Sanam ; Lin, Pei ; Jabbour, Elias J. ; Khoury, Joseph D.</creatorcontrib><description>Summary
B‐cell lymphoma/leukaemia 11B (BCL11B) is an essential transcription factor for T‐cell lineage commitment and maturation. We investigated BCL11B expression by immunohistochemistry in T‐lymphoblastic leukaemia/lymphoma (T‐ALL/LBL) (n = 115). The majority (83%) of early T‐cell precursor T‐ALL/LBL (ETP‐ALL) cases showed negative BCL11B expression, while most (84%) of non‐ETP‐ALL/LBL were positive for BCL11B. A simplified three‐marker [BCL11B, cluster of differentiation 5 (CD5), CD13] immunophenotypic score discriminated reliably between ETP‐ALL and non‐ETP‐ALL/LBL. In ETP‐ALL, patients with positive BCL11B expression had a better overall survival than those with negative BCL11B (P = 0·009). In summary, BCL11B is a valuable marker for T‐ALL/LBL subtyping and serves as a potential prognostic marker in patients with ETP‐ALL.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.17681</identifier><identifier>PMID: 34402058</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Acute lymphoblastic leukemia ; B-cell lymphoma ; BCL11B ; CD13 antigen ; CD5 antigen ; Cell lineage ; Cohort Studies ; early T‐cell precursor lymphoblastic leukaemia ; Hematology ; Humans ; Immunohistochemistry ; Leukemia ; Lymphoma ; Precursor Cells, T-Lymphoid - pathology ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology ; Prognosis ; Repressor Proteins - analysis ; Tumor Suppressor Proteins - analysis ; T‐cell differentiation ; T‐lymphoblastic leukaemia/lymphoma</subject><ispartof>British journal of haematology, 2021-09, Vol.194 (6), p.1034-1038</ispartof><rights>2021 British Society for Haematology and John Wiley & Sons Ltd</rights><rights>2021 British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-633a5a39f5aa468315a902932cceb7f6681fa0983213f58fda49cbb879dd24113</citedby><cites>FETCH-LOGICAL-c3881-633a5a39f5aa468315a902932cceb7f6681fa0983213f58fda49cbb879dd24113</cites><orcidid>0000-0001-8980-3202 ; 0000-0001-6821-4556 ; 0000-0003-2621-3584 ; 0000-0003-1780-5959</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.17681$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.17681$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34402058$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fang, Hong</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>El Hussein, Siba</creatorcontrib><creatorcontrib>Morita, Kiyomi</creatorcontrib><creatorcontrib>Beird, Hannah C.</creatorcontrib><creatorcontrib>Mitra, Akash</creatorcontrib><creatorcontrib>Loghavi, Sanam</creatorcontrib><creatorcontrib>Lin, Pei</creatorcontrib><creatorcontrib>Jabbour, Elias J.</creatorcontrib><creatorcontrib>Khoury, Joseph D.</creatorcontrib><title>B‐cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T‐cell precursor acute lymphoblastic leukaemia/lymphoma (ETP‐ALL/LBL) from other subtypes of T‐cell ALL/LBL</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
B‐cell lymphoma/leukaemia 11B (BCL11B) is an essential transcription factor for T‐cell lineage commitment and maturation. We investigated BCL11B expression by immunohistochemistry in T‐lymphoblastic leukaemia/lymphoma (T‐ALL/LBL) (n = 115). The majority (83%) of early T‐cell precursor T‐ALL/LBL (ETP‐ALL) cases showed negative BCL11B expression, while most (84%) of non‐ETP‐ALL/LBL were positive for BCL11B. A simplified three‐marker [BCL11B, cluster of differentiation 5 (CD5), CD13] immunophenotypic score discriminated reliably between ETP‐ALL and non‐ETP‐ALL/LBL. In ETP‐ALL, patients with positive BCL11B expression had a better overall survival than those with negative BCL11B (P = 0·009). In summary, BCL11B is a valuable marker for T‐ALL/LBL subtyping and serves as a potential prognostic marker in patients with ETP‐ALL.</description><subject>Acute lymphoblastic leukemia</subject><subject>B-cell lymphoma</subject><subject>BCL11B</subject><subject>CD13 antigen</subject><subject>CD5 antigen</subject><subject>Cell lineage</subject><subject>Cohort Studies</subject><subject>early T‐cell precursor lymphoblastic leukaemia</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Precursor Cells, T-Lymphoid - pathology</subject><subject>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</subject><subject>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology</subject><subject>Prognosis</subject><subject>Repressor Proteins - analysis</subject><subject>Tumor Suppressor Proteins - analysis</subject><subject>T‐cell differentiation</subject><subject>T‐lymphoblastic leukaemia/lymphoma</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhS0EotPCghdAltjMLNL42s7fshkVCopUFsM6chyHZEjGwY5VsuMReKg-CU9ST2emSEi9m7v5zjlX9yD0Dsgl-AmrbXsJSZzCC7QAFkcBBQ4v0YIQkgRAeHqGzq3dEgKMRPAanTHOCSVRukD3-d_ff6Tqe9zPw9jqQYS9cj-EGjqBAXK8zNeF3yusfo1GWdvpHbaTmJzFrepHi-vOTt3uu-tsi5Uw_Yw3J0svkM5YbbCQblLHiKoXXiHxU054isbL681XL74qirDIixVujB6wnlplsHXVNI_KYt38CziCb9CrRvRWvT3uC_Tt4_VmfRMUt58-r6-KQLI0hSBmTESCZU0kBI9TBpHICM0YlVJVSRP7BzaCZCmjwJoobWrBM1lVaZLVNeUA7AItD76j0T-dslM5dHZ_iNgp7WxJo5hS_1vOPfrhP3Srndn56zyV0CxKIN4brg6UNNpao5pyNN0gzFwCKffVlr7a8rFaz74_OrpqUPUTeerSA-EBuOt6NT_vVOZfbg6WDwapsN0</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Fang, Hong</creator><creator>Wang, Wei</creator><creator>El Hussein, Siba</creator><creator>Morita, Kiyomi</creator><creator>Beird, Hannah C.</creator><creator>Mitra, Akash</creator><creator>Loghavi, Sanam</creator><creator>Lin, Pei</creator><creator>Jabbour, Elias J.</creator><creator>Khoury, Joseph D.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8980-3202</orcidid><orcidid>https://orcid.org/0000-0001-6821-4556</orcidid><orcidid>https://orcid.org/0000-0003-2621-3584</orcidid><orcidid>https://orcid.org/0000-0003-1780-5959</orcidid></search><sort><creationdate>202109</creationdate><title>B‐cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T‐cell precursor acute lymphoblastic leukaemia/lymphoma (ETP‐ALL/LBL) from other subtypes of T‐cell ALL/LBL</title><author>Fang, Hong ; Wang, Wei ; El Hussein, Siba ; Morita, Kiyomi ; Beird, Hannah C. ; Mitra, Akash ; Loghavi, Sanam ; Lin, Pei ; Jabbour, Elias J. ; Khoury, Joseph D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-633a5a39f5aa468315a902932cceb7f6681fa0983213f58fda49cbb879dd24113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>B-cell lymphoma</topic><topic>BCL11B</topic><topic>CD13 antigen</topic><topic>CD5 antigen</topic><topic>Cell lineage</topic><topic>Cohort Studies</topic><topic>early T‐cell precursor lymphoblastic leukaemia</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Precursor Cells, T-Lymphoid - pathology</topic><topic>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis</topic><topic>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology</topic><topic>Prognosis</topic><topic>Repressor Proteins - analysis</topic><topic>Tumor Suppressor Proteins - analysis</topic><topic>T‐cell differentiation</topic><topic>T‐lymphoblastic leukaemia/lymphoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fang, Hong</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>El Hussein, Siba</creatorcontrib><creatorcontrib>Morita, Kiyomi</creatorcontrib><creatorcontrib>Beird, Hannah C.</creatorcontrib><creatorcontrib>Mitra, Akash</creatorcontrib><creatorcontrib>Loghavi, Sanam</creatorcontrib><creatorcontrib>Lin, Pei</creatorcontrib><creatorcontrib>Jabbour, Elias J.</creatorcontrib><creatorcontrib>Khoury, Joseph D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fang, Hong</au><au>Wang, Wei</au><au>El Hussein, Siba</au><au>Morita, Kiyomi</au><au>Beird, Hannah C.</au><au>Mitra, Akash</au><au>Loghavi, Sanam</au><au>Lin, Pei</au><au>Jabbour, Elias J.</au><au>Khoury, Joseph D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>B‐cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T‐cell precursor acute lymphoblastic leukaemia/lymphoma (ETP‐ALL/LBL) from other subtypes of T‐cell ALL/LBL</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2021-09</date><risdate>2021</risdate><volume>194</volume><issue>6</issue><spage>1034</spage><epage>1038</epage><pages>1034-1038</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
B‐cell lymphoma/leukaemia 11B (BCL11B) is an essential transcription factor for T‐cell lineage commitment and maturation. We investigated BCL11B expression by immunohistochemistry in T‐lymphoblastic leukaemia/lymphoma (T‐ALL/LBL) (n = 115). The majority (83%) of early T‐cell precursor T‐ALL/LBL (ETP‐ALL) cases showed negative BCL11B expression, while most (84%) of non‐ETP‐ALL/LBL were positive for BCL11B. A simplified three‐marker [BCL11B, cluster of differentiation 5 (CD5), CD13] immunophenotypic score discriminated reliably between ETP‐ALL and non‐ETP‐ALL/LBL. In ETP‐ALL, patients with positive BCL11B expression had a better overall survival than those with negative BCL11B (P = 0·009). In summary, BCL11B is a valuable marker for T‐ALL/LBL subtyping and serves as a potential prognostic marker in patients with ETP‐ALL.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>34402058</pmid><doi>10.1111/bjh.17681</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-8980-3202</orcidid><orcidid>https://orcid.org/0000-0001-6821-4556</orcidid><orcidid>https://orcid.org/0000-0003-2621-3584</orcidid><orcidid>https://orcid.org/0000-0003-1780-5959</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2021-09, Vol.194 (6), p.1034-1038 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2562234444 |
| source | MEDLINE; Access via Wiley Online Library; Wiley Free Content |
| subjects | Acute lymphoblastic leukemia B-cell lymphoma BCL11B CD13 antigen CD5 antigen Cell lineage Cohort Studies early T‐cell precursor lymphoblastic leukaemia Hematology Humans Immunohistochemistry Leukemia Lymphoma Precursor Cells, T-Lymphoid - pathology Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology Prognosis Repressor Proteins - analysis Tumor Suppressor Proteins - analysis T‐cell differentiation T‐lymphoblastic leukaemia/lymphoma |
| title | B‐cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T‐cell precursor acute lymphoblastic leukaemia/lymphoma (ETP‐ALL/LBL) from other subtypes of T‐cell ALL/LBL |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T18%3A20%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=B%E2%80%90cell%20lymphoma/leukaemia%2011B%20(BCL11B)%20expression%20status%20helps%20distinguish%20early%20T%E2%80%90cell%20precursor%20acute%20lymphoblastic%20leukaemia/lymphoma%20(ETP%E2%80%90ALL/LBL)%20from%20other%20subtypes%20of%20T%E2%80%90cell%20ALL/LBL&rft.jtitle=British%20journal%20of%20haematology&rft.au=Fang,%20Hong&rft.date=2021-09&rft.volume=194&rft.issue=6&rft.spage=1034&rft.epage=1038&rft.pages=1034-1038&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.17681&rft_dat=%3Cproquest_cross%3E2562234444%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2572957161&rft_id=info:pmid/34402058&rfr_iscdi=true |